Search

Your search keyword '"Foà R"' showing total 1,206 results
Start Over Author "Foà R"
1,206 results on '"Foà R"'

51. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

52. EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY

Author

Visentin, A., primary, Mauro, F. R., additional, Cibien, F., additional, Vitale, C., additional, Reda, G., additional, Fresa, A., additional, Ciolli, S., additional, Pietrasanta, D., additional, Marchetti, M., additional, Murru, R., additional, Gentile, M., additional, Rigolin, G. M., additional, Quaglia, F. M., additional, Scarfò, L., additional, Sportoletti, P., additional, Pravato, S., additional, Romano Gargarella, L., additional, Facco, M., additional, Piazza, F., additional, Coscia, M., additional, Laurenti, L., additional, Molica, S., additional, Pizzolo, G., additional, Foà, R., additional, Cuneo, A., additional, and Trentim, L., additional

Published
2021
Full Text
View/download PDF

53. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia

Author

Della Starza, I, Nunes, V, Lovisa, F, Silvestri, D, Cavalli, M, Garofalo, A, Campeggio, M, De Novi, L, Soscia, R, Oggioni, C, Mussolin, L, Biondi, A, Guarini, A, Valsecchi, M, Conter, V, Biffi, A, Basso, G, Foà, R, Cazzaniga, G, Della Starza, Irene, Nunes, Vittorio, Lovisa, Federica, Silvestri, Daniela, Cavalli, Marzia, Garofalo, Andrea, Campeggio, Mimma, De Novi, Lucia Anna, Soscia, Roberta, Oggioni, Carlotta, Mussolin, Lara, Biondi, Andrea, Guarini, Anna, Valsecchi, Maria Grazia, Conter, Valentino, Biffi, Alessandra, Basso, Giuseppe, Foà, Robin, Cazzaniga, Giovanni, Della Starza, I, Nunes, V, Lovisa, F, Silvestri, D, Cavalli, M, Garofalo, A, Campeggio, M, De Novi, L, Soscia, R, Oggioni, C, Mussolin, L, Biondi, A, Guarini, A, Valsecchi, M, Conter, V, Biffi, A, Basso, G, Foà, R, Cazzaniga, G, Della Starza, Irene, Nunes, Vittorio, Lovisa, Federica, Silvestri, Daniela, Cavalli, Marzia, Garofalo, Andrea, Campeggio, Mimma, De Novi, Lucia Anna, Soscia, Roberta, Oggioni, Carlotta, Mussolin, Lara, Biondi, Andrea, Guarini, Anna, Valsecchi, Maria Grazia, Conter, Valentino, Biffi, Alessandra, Basso, Giuseppe, Foà, Robin, and Cazzaniga, Giovanni

Abstract

Minimal residual disease (MRD) is the most powerful prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Real-time quantitative polymerase chain reaction (RQ-PCR) represents the gold standard for molecular MRD assessment and risk-based stratification of front-line treatment. In the protocols of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and the Berlin-Frankfurth-Munschen (BFM) group AIEOP-BFM ALL2009 and ALL2017, B-lineage ALL patients with high RQ-PCR-MRD at day+33 and positive at day+78 are defined slow early responders (SERs). Based on results of the AIEOP-BFM ALL2000 study, these patients are treated as high-risk also when positive MRD signal at day +78 is below the lower limit of quantification of RQ-PCR ("positive not-quantifiable," POS-NQ). To assess whether droplet digital polymerase chain reaction (ddPCR) could improve patients' risk definition, we analyzed MRD in 209 pediatric B-lineage ALL cases classified by RQ-PCR as POS-NQ and/or negative (NEG) at days +33 and/or +78 in the AIEOP-BFM ALL2000 trial. ddPCR MRD analysis was performed on 45 samples collected at day +78 from SER patients, who had RQ-PCR MRD ≥ 5.0 * 10-4 at day+33 and POS-NQ at day+78 and were treated as medium risk (MR). The analysis identified 13 of 45 positive quantifiable cases. Most relapses occurred in this patients' subgroup, while ddPCR NEG or ddPCR-POS-NQ patients had a significantly better outcome (P < 0.001). Overall, in 112 MR cases and 52 standard-risk patients, MRD negativity and POS-NQ were confirmed by the ddPCR analysis except for a minority of cases, for whom no differences in outcome were registered. These data indicate that ddPCR is more accurate than RQ-PCR in the measurement of MRD, particularly in late follow-up time points, and may thus allow improving patients' stratification in ALL protocols.

Published
2021

66. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding

Author

Boriani, G, Corradini, P, Cuneo, A, Falanga, A, Foà, R, Gaidano, G, Ghia, P, Martelli, M, Marasca, R, Massaia, M, Mauro, F, Minotti, G, Molica, S, Montillo, M, Pinto, A, Tedeschi, A, Vitolo, U, Zinzani, P, Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL, Boriani, G, Corradini, P, Cuneo, A, Falanga, A, Foà, R, Gaidano, G, Ghia, P, Martelli, M, Marasca, R, Massaia, M, Mauro, F, Minotti, G, Molica, S, Montillo, M, Pinto, A, Tedeschi, A, Vitolo, U, Zinzani, P, Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, and Zinzani PL

Abstract

The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment of patients with chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenström macroglobulinemia, significantly improving clinical outcomes. However, IB therapy has been associated with an increased risk of atrial fibrillation (AF) and bleeding. We report on the expert opinion that a group of Italian haematologists, cardiologists, and pharmacologists jointly released to improve the practical management of patients at risk for AF and bleeding during treatment with IB. A proper pretreatment assessment to identify patients who are at a higher risk, careful choice of concomitant drugs, regular monitoring, and multispecialist approach were characterized as the main principles of clinical management of these patients. For patients developing AF, anticoagulant and antiarrhythmic therapy must be guided by considerations about efficacy, safety, and risk of pharmacokinetic interactions with IB. For patients experiencing bleeding or requiring procedures that increase the risk of bleeding, considerations about platelet turnover, IB-related platelet dysfunctions, and bleeding worsening by concomitant anticoagulants or antiplatelet agents provide clues to manage bleeding. Overall, AF and bleeding are manageable clinical events in patients receiving IB, not requiring drug interruption in most cases. Preexisting AF should not represent an absolute contraindication to IB therapy. For each patient candidate for IB, strategies of risk assessment and mitigation may allow to exploit the life-saving effects of in chronic lymphocytic leukaemia and mantle cell lymphoma

Published
2018

67. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib

Author

Giona, F, Saglio, G, Santopietro, M, Menna, G, Putti, M, Micalizzi, C, Iaria, G, Santoro, N, Ladogana, S, Mura, R, Burnelli, R, Consarino, C, Cosmi, C, Moleti, M, Leszl, A, Tucci, F, Nanni, M, Diverio, D, Biondi, A, Locatelli, F, Foà, R, BIONDI, ANDREA, Foà, R., Giona, F, Saglio, G, Santopietro, M, Menna, G, Putti, M, Micalizzi, C, Iaria, G, Santoro, N, Ladogana, S, Mura, R, Burnelli, R, Consarino, C, Cosmi, C, Moleti, M, Leszl, A, Tucci, F, Nanni, M, Diverio, D, Biondi, A, Locatelli, F, Foà, R, BIONDI, ANDREA, and Foà, R.

Published
2018

68. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Author

Breccia, M, Abruzzese, E, Castagnetti, F, Bonifacio, M, Gangemi, D, Sorà, F, Iurlo, A, Luciano, L, Gozzini, A, Gentile, M, Bocchia, M, Luzi, D, Maggi, A, Sgherza, N, Isidori, A, Crugnola, M, Pregno, P, Scortechini, Ar, Capodanno, I, Pizzuti, M, Foà, R., Sorà F (ORCID:0000-0002-9607-5298), Gentile M, Pizzuti M, Foà R., Breccia, M, Abruzzese, E, Castagnetti, F, Bonifacio, M, Gangemi, D, Sorà, F, Iurlo, A, Luciano, L, Gozzini, A, Gentile, M, Bocchia, M, Luzi, D, Maggi, A, Sgherza, N, Isidori, A, Crugnola, M, Pregno, P, Scortechini, Ar, Capodanno, I, Pizzuti, M, Foà, R., Sorà F (ORCID:0000-0002-9607-5298), Gentile M, Pizzuti M, and Foà R.

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32-72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

Published
2018

72. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report: O133

Author

Iacobucci, I., Lonetti, A., Ferrari, A., Vignetti, M., Storlazzi, C. T., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., Astolfi, A., Testoni, N., Papayannidis, C., Paolini, S., Piccaluga, PP., Elia, L., Messa, F., DellʼAgnola, C., Cingarlini, S., Meloni, G., Leone, G., Amadori, S., Russo, D., Saglio, G., Pane, F., Baccarani, M., Foà, R., and Martinelli, G.

Published
2009

73. pH-positive acute lymphoblastic leukaemia is characterised by recurrent copy number anomalies in genes regulating the cell cycle and B-cell differentiation: O138

Author

Iacobucci, I., Ottaviani, E., Lonetti, A., Ferrari, A., Astolfi, A., Storlazzi, CT., Testoni, N., Paolini, S., Papayannidis, C., Cilloni, D., Messa, F., Soverini, S., Arruga, F., Pane, F., Vitale, A., Messina, M., Chiaretti, S., Piccaluga, PP., DellʼAgnola, C., Cingarlini, S., Foà, R., Baccarani, M., and Martinelli, G.

Published
2009

78. Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape

Author

Morelli, F, Innocenti, I, Autore, F, Fresa, F, Tomasso, A, Piciocchi, A, Frustaci, Am, Trentin, L, Mauro, Fr, Schiattone, L, Visentin, A, Del Poeta, G, Reda, G, Rigolin, Gm, Ibatici, A, Ciolli, S, Vitale, C, Sportoletti, P, Murru, R, Levato, L, Gentile, M, D’Arena, G, Coscia, M, Villa, Mr, Fontana, R, Efremov, D, Tedeschi, A, Scarfò, L, Cuneo, A, Foà, R, and Laurenti, L

Published
2020

85. Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia

Author

Hijiya, N, Michel Zwaan, C, Rizzari, C, Foà, R, Abbink, F, Lancaster, D, Landman-Parker, J, Millot, F, Moppett, J, Nelken, B, Putti, M, Xianbin, T, Sinclair, K, Santanastasio, H, Buchbinder, A, Kearns, P, Michel Zwaan,CM, Putti, MC, Hijiya, N, Michel Zwaan, C, Rizzari, C, Foà, R, Abbink, F, Lancaster, D, Landman-Parker, J, Millot, F, Moppett, J, Nelken, B, Putti, M, Xianbin, T, Sinclair, K, Santanastasio, H, Buchbinder, A, Kearns, P, Michel Zwaan,CM, and Putti, MC

Abstract

Purpose: We investigated nilotinib exposure in pediatric patients with chronic myeloid leukemia (CML) or Philadelphia chromosome–positive (Phþ) acute lymphoblastic leukemia (ALL) resistant to, relapsed on, refractory to, or intolerant of previous treatment. Patients and Methods: Fifteen patients (aged 1–<18 years) with CML resistant to or intolerant of imatinib and/or dasatinib (n 1⁄4 11) or Phþ ALL relapsed on or refractory to standard therapy (n 1⁄4 4) enrolled in this phase I study. Nilotinib (230 mg/m2 twice daily; equivalent to the adult 400-mg twice-daily dose) was administered orally in 12 or 24 cycles of 28 days. The primary objective was to characterize the pharmacokinetics of nilotinib in pediatric patients. Results: The area under the concentration–time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70–1.06]. Body surface area–adjusted systemic clearance was slightly higher in pediatric versus adult patients (GMR, 1.30; 90% CI, 1.04–1.62). Nilotinib was generally well tolerated. The most common adverse events were headache, vomiting, increased blood bilirubin, and rash. Three patients with CML achieved major molecular response, and three with Phþ ALL achieved complete remission. Conclusions: Nilotinib 230 mg/m2 twice daily in pediatric patients provided a pharmacokinetics and safety profile comparable with the adult reference dose; clinical activity was demonstrated in both CML and Phþ ALL. This dose is recommended for further evaluation in pediatric patients. The safety profile was consistent with that in adults.

Published
2020

88. S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Author

Tiacci, E., primary, De Carolis, L., additional, Simonetti, E., additional, Zaja, F., additional, Capponi, M., additional, Ambrosetti, A., additional, Lucia, E., additional, Antolino, A., additional, Pulsoni, A., additional, Ferrari, S., additional, Zinzani, P. L., additional, Rigacci, L., additional, Gaidano, G., additional, Della Seta, R., additional, Frattarelli, N., additional, Falcucci, P., additional, Visani, G., additional, Foà, R., additional, and Falini, B., additional

Published
2019
Full Text
View/download PDF

89. PF174 GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL

Author

Chiaretti, S., primary, Cesini, L., additional, Di Raimondo, F., additional, Angelucci, E., additional, Luppi, M., additional, Bonifacio, M., additional, Cascavilla, N., additional, Fozza, C., additional, La Sala, E., additional, Soddu, S., additional, Fazi, P., additional, Vitale, A., additional, Foà, R., additional, and Ferrara, F., additional

Published
2019
Full Text
View/download PDF

90. PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

Author

Palandri, F., primary, Breccia, M., additional, Bonifacio, M., additional, Polverelli, N., additional, Elli, E.M., additional, Benevolo, G., additional, Tiribelli, M., additional, Abruzzese, E., additional, Iurlo, A., additional, Heidel, F., additional, Bergamaschi, M., additional, Tieghi, A., additional, Crugnola, M., additional, Cavazzini, F., additional, Binotto, G., additional, Isidori, A., additional, Sgherza, N., additional, Bosi, C., additional, Martino, B., additional, Latagliata, R., additional, Auteri, G., additional, Scaffidi, L., additional, Griguolo, D., additional, Trawinska, M., additional, Cattaneo, D., additional, Catani, L., additional, Krampera, M., additional, Vitolo, U., additional, Lemoli, R.M., additional, Cuneo, A., additional, Semenzato, G., additional, Foà, R., additional, Raimondo, F. Di, additional, Bartoletti, D., additional, Cavo, M., additional, Palumbo, G.A., additional, and Vianelli, N., additional

Published
2019
Full Text
View/download PDF

91. S1617 A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY

Author

Chiaretti, S., primary, Bassan, R., additional, Vitale, A., additional, Elia, L., additional, Piciocchi, A., additional, Ferrara, F., additional, Lunghi, M., additional, Fabbiano, F., additional, Bonifacio, M., additional, Fracchiolla, N., additional, Salutari, P., additional, Mancino, A., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

92. PF359 TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT

Author

Cafforio, L., primary, Cappelli, L.V., additional, Del Giudice, I., additional, Ilari, C., additional, Raponi, S., additional, De Propris, M.S., additional, Mariglia, P., additional, Mauro, F.R., additional, Piciocchi, A., additional, Giuliani, G., additional, Vignetti, M., additional, Guarini, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

93. PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Author

Mauro, F.R., primary, Molica, S., additional, Paoloni, F., additional, Reda, G., additional, Trentin, L., additional, Marchetti, M., additional, Pietrasanta, D., additional, Coscia, M., additional, Marasca, R., additional, Sportoletti, P., additional, Gaidano, G., additional, Orsucci, L., additional, Stelitano, C., additional, Di Renzo, N., additional, Liberati, A.M., additional, Gottardi, D., additional, Re, F., additional, Ilariucci, F., additional, Zinzani, P., additional, Mannina, D., additional, Gozzetti, A., additional, Molinari, A.L., additional, Gentile, M., additional, Consoli, U., additional, Laurenti, L., additional, Arcaini, L., additional, Ibatici, A., additional, Murru, R., additional, Tani, M., additional, De Propris, M.S., additional, Del Giudice, I., additional, Della Starza, I., additional, Raponi, S., additional, Nanni, M., additional, Fazi, P., additional, Crea, E., additional, Neri, A., additional, Specchia, G., additional, Guarini, A.R., additional, Cuneo, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

94. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Author

Tiacci, E., primary, De Carolis, L., additional, Simonetti, E., additional, Zaja, F., additional, Capponi, M., additional, Ambrosetti, A., additional, Lucia, E., additional, Antolino, A., additional, Pulsoni, A., additional, Ferrari, S., additional, Zinzani, P., additional, Rigacci, L., additional, Gaidano, G., additional, Della Seta, R., additional, Frattarelli, N., additional, Falcucci, P., additional, Visani, G., additional, Foà, R., additional, and Falini, B., additional

Published
2019
Full Text
View/download PDF

95. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A)

Author

Condoluci, A., primary, Terzi di Bergamo, L., additional, Langerbeins, P., additional, Hoechstetter, M., additional, Herling, C., additional, De Paoli, L., additional, Delgado, J., additional, Gentile, M., additional, Doubek, M., additional, Mauro, F.R., additional, Chiodin, G., additional, Mattsson, M., additional, Bahlo, J., additional, Cutrona, G., additional, Kotaskova, J., additional, Deambrogi, C., additional, Moia, R., additional, Gerber, B., additional, Zucca, E., additional, Ghielmini, M., additional, Cavalli, F., additional, Stüssi, G., additional, Neri, A., additional, Ferrarini, M., additional, Rosenquist, R., additional, Forconi, F., additional, Foà, R., additional, Pospisilova, S., additional, Morabito, F., additional, Wierda, W.G., additional, Montserrat, E., additional, Gaidano, G., additional, Hallek, M., additional, and Rossi, D., additional

Published
2019
Full Text
View/download PDF

96. S1620 NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.

Author

Candoni, A., primary, Lazzarotto, D., additional, Curti, A., additional, Ferrara, F., additional, Lussana, F., additional, Papayannidis, C., additional, Del Principe, M.I., additional, Bonifacio, M., additional, Mosna, F., additional, Delia, M., additional, Minetto, P., additional, Gottardi, M., additional, Fracchiolla, N., additional, Mancini, V., additional, Forghieri, F., additional, Zappasoldi, P., additional, Cerrano, M., additional, Vitale, A., additional, Audisio, E., additional, Trappolini, S., additional, Romani, C., additional, Defina, M., additional, Imbergamo, S., additional, Ciccone, N., additional, Santoro, L., additional, Cambò, B., additional, Iaccarino, S., additional, Dargenio, M., additional, Aprile, L., additional, Pizzolo, G., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

98. PS1152 THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE

Author

Innocenti, I., primary, Morelli, F., additional, Autore, F., additional, Piciocchi, A., additional, Frustaci, A., additional, Mauro, F.R., additional, Schiattone, L., additional, Trentin, L., additional, Poeta, G. Del, additional, Reda, G., additional, Rigolin, G.M., additional, Ibatici, A., additional, Ciolli, S., additional, Coscia, M., additional, Sportoletti, P., additional, Murru, R., additional, Levato, L., additional, Gentile, M., additional, D’Arena, G., additional, Villa, M.R., additional, Fontana, R., additional, Tedeschi, A., additional, Scarfò, L., additional, Cuneo, A., additional, Foà, R., additional, and Laurenti, L., additional

Published
2019
Full Text
View/download PDF

99. PF365 PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH “BORDERLINE” PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Author

Raponi, S., primary, Ilari, C., additional, Della Starza, I., additional, Del Giudice, I., additional, Cappelli, L.V., additional, Cafforio, L., additional, Piciocchi, A., additional, Bontempi, K., additional, Cavalli, M., additional, De Novi, L.A., additional, Mariglia, P., additional, Mauro, F.R., additional, Gentile, M., additional, Cutrona, G., additional, Moia, R., additional, Rossi, D., additional, Gaidano, G., additional, Morabito, F., additional, Guarini, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

100. PS935 APPLICABILITY OF DROPLET DIGITAL PCR (DDPCR) FOR MINIMAL RESIDUAL DISEASE MONITORING (MRD) IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Author

Chiaretti, S., primary, Lauretti, A., additional, Della Starza, I.D. S., additional, Elia, L., additional, Messina, M., additional, Siravo, V., additional, Ansuinelli, M., additional, De Novi, L., additional, Cavalli, M., additional, Canichella, M., additional, Guarini, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results